Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood-flow cuffs may mimic exercise to ease Parkinson's symptoms

NCT ID NCT06293118

Symptom relief Sponsor: Hospital Israelita Albert Einstein Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This trial tests whether ischemic conditioning — brief cycles of blood-flow restriction using pressure cuffs on the arms — can improve motor function and cognitive performance in people with Parkinson's disease. Over 12 weeks, 34 participants will receive 24 sessions of the therapy. Researchers will also measure effects on mobility, quality of life, and immune responses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ischemic conditioning using a KAATSU C3 device
What this could lead to
If it works, this could offer a non-drug, exercise-like therapy to help manage motor and cognitive symptoms in Parkinson's disease.
What could go wrong
This is a small, early-stage trial with only 34 participants. The effects may be modest, and the repeated cuff inflations could cause discomfort or bruising.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PD patients aged 40 years or older; * Diagnosis of PD without cognitive complaints or with complaints, but without impact on daily activities; Exclusion Criteria: * Patients with uncontrolled diabetes mellitus or peripheral neuropathy; * Uncontrolled arterial hypertension (BP\>160/100mmHg); * Uncontrolled diabetes (Fasting glucose \> 250mg/dl, peripheral retinopathy or diabetic ketoacidosis); * Uncontrolled dyslipidemia (total chol \> 220mg/dL); * Pre-existing autoimmune diseases; * Infectious conditions for less than 1 month; * Neurological problems that prevent training from being carried out; * History of anemia, cerebral vascular disease, myocardial infarction in the last 6 months; * Previous deep vein thrombosis; * Smoking \< 6 months; * Symptomatic peripheral arterial obstructive disease; * Cognitive dysfunction: Moca \< 24.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.